Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2020-03-20 Capital/Financing Update
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and prospectus related to a securities offering, specifically an At Market Issuance Sales Agreement for common stock with a maximum aggregate offering price of $200 million. It includes details about the offering, risk factors, use of proceeds, plan of distribution, and legal matters. The document is filed pursuant to Rule 424(b)(5) under the Securities Act of 1933 and is a registration statement update. This type of document is a capital raising and financing update rather than a financial report, earnings release, or other regulatory filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is not merely an announcement but the actual offering document.
2020-03-20 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 20, 2020, by TG Therapeutics, Inc. It announces the launch of an 'at the market' offering of common stock pursuant to a Sales Agreement with several agents. The document includes a description of the offering, the commission rate, and references to exhibits such as the Sales Agreement and legal opinion. There are no financial statements or detailed financial results presented, only an announcement of a financing activity. This fits the definition of a Capital/Financing Update (CAP) as it provides an update on the company's fundraising and capital structure changes. The document length is under 5,000 characters but contains substantive information about the financing event itself, not just a report publication announcement or a regulatory filing. Therefore, the correct classification is CAP with high confidence.
2020-03-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 3, 2020, by TG Therapeutics, Inc. It announces the issuance of a press release with results of operations for the fourth quarter and year ended December 31, 2019, and mentions an upcoming investor conference call. The document itself does not contain detailed financial statements or substantive financial data but rather announces the results and the press release. The length is 3083 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing results and a press release, not the earnings release itself or a full financial report.
2020-03-03 English
10-K
Annual Report FY 2019
2020-03-02 English
SC 13G/A
Major Shareholding Notification
2020-02-14 English
SCHEDULE 13G HOLDINGS REPORT AMENDMENT
Major Shareholding Notification
2020-02-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.